Tag: IOVA

Analysts Viewpoint

UBS’s latest rating for IOVA stock

Iovance Biotherapeutics Inc’s recent filing unveils that its Chief Commercial Officer Kirby Daniel Gordon acquired Company’s shares for reported $55200.0

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.